Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports

Figure 1 Changes in serum potassium and creatinine levels before and during nafamostat mesylate administration. Serum potassium levels increased in all four patients on the third day of NM administration without acute kidney disease. A: Serum potassium; B: Serum creatinine. Cre: Creatinine; NM: Nafamostat mesylate; K: Potassium.